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of the side effects during treatment period. 
CONCLUSION: S. boulardii  significantly reduces the fre-
quency and duration of acute diarrhoea. The consistency 
of stool also improves. The drug is well-tolerated.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Acute infectious diarrhoeal disease is a worldwide problem 
with over two million deaths each year. Diarrhoeal diseases 
are a leading cause of  childhood morbidity and mortality 
and over 200 000 children die every year (600 deaths per 
day) in Pakistan. Repeated episodes of  diarrhoea lead to 
under-nutrition. In Pakistan, every child gets, on average, 
5-6 episodes of  diarrhoea per year.
Last couple of  decades has seen greater understand-
ing of  pathogenesis and simple methods of  management 
of  diarrhoea. Various modalities of  interventions have 
been used in different parts of  the world to improve the 
diarrhoeal mortality and morbidity which include oral 
rehydration salt (ORS), cereal based ORS, antibiotics, 
anti-diarrhoeals, antispasmodics and anti-emetics. Some 
of  these modalities later proved to have variable harmful 
effects. These harmful effects include worsening of  diar-
rhoea, increased duration of  diarrhoea, adverse effects on 
gut motility leading to paralytic ileus. In addition, there are 
other systemic untoward effects[1,2].  
Gastrointestinal disease is often a consequence of  
a myriad of  factors, which disturb the bowel’s complex 
ecosystem. The concept of  modulating bacterial activities, 
directed towards improving gut microbial function, has a 
long history. The use of  yoghurt (as probiotic) in the treat-
ment of  diarrhoea has been known for a long time. It is 
now recognised that the most frequently used method of  
influencing the gut flora composition is that of  probiot-
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Abstract
AIM: To assess the efficacy and safety of Saccharomyces 
boulardii (S. boulardii ) in acute watery diarrhoea and its 
role in reducing the frequency of episodes of diarrhoea 
in subsequent two months.
METHODS: Children from 2 mo to 12 years of age, with 
acute diarrhoea were selected according to inclusion cri-
teria and randomised in S. boulardii group (treated with 
ORS, nutritional support and S. boulardii , 250 mg bid) 
and in control group (treated with ORS and nutritional 
support only). Active treatment phase was 5 d and each 
child was followed for two months afterwards. Frequency 
and consistency of stools as well as safety of drug was 
assessed on every visit. A comparison of two groups was 
done in terms of number of diarrhoeal episode in subse-
quent two months.
RESULTS: There were fifty patients in each group. Base-
line characteristics such as mean age and the average 
frequency of stools were comparable in S. boulardii  and 
control group at the time of inclusion in the trial.  By d 3 
it reduced to 2.7 and 4.2 stools per d respectively and by 
d 6 it reduced to 1.6 (S. boulardii  Group) and 3.3 (control 
group). The duration of diarrhoea was 3.6 d in S. bou-
lardii  group whereas it was 4.8 d in control group (P = 
0.001). In the following two months, S. boulardii group 
had a significantly lower frequency of 0.54 episodes as 
compared to 1.08 episodes in control group. The drug 
was well accepted and tolerated. There were no reports 
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ics. A probiotic is a living micro organism administered to 
promote the health of  the host by treating or preventing 
infections owing to strains of  pathogens[3]. Bio-therapeutic 
agents are defined as probiotics registered as drugs.
The modern view of  probiotic therapy derives from 
the concept of  a well functioning gut barrier and a normal 
balanced microbiota.
Numerous probiotic agents have been studied for 
the management of  diarrhoeal disease. In particular, the 
prevention and management of  acute viral diarrhoea, 
the treatment of  recurrent Clostridium difficile diarrhoea, 
as well as the control of  antibiotic-associated diarrhoea 
seem to be areas of  significant potential benefit. A few 
agents, including Lactobacillus GG, Lactobacillus reuteri, and 
Saccharomyces boulardii (S. boulardii), seem to be promising 
agents for the amelioration of  the course of  acute 
diarrhoea in children when used therapeutically[4]. Amongst 
these, all are bacteria except S. boulardii, which is yeast.
S. boulardii is a non-pathogenic yeast first isolated from 
lychee fruits in Indonesia and used first in France to treat 
diarrhoea, in the beginning of  the 1950s. A lyophilised 
form is in clinical use in Europe, Asia, Africa, and Central 
and South America. 
Preclinical and experimental studies of  S. boulardii 
have demonstrated an anti-inflammatory, antimicrobial, 
enzymatic, metabolic and antitoxinic activity. S. boulardii 
secretes a 54-KDa protease which has been shown to 
neutralize certain bacterial toxins; S. boulardii is also able to 
stimulate an immune response in the intestinal mucosa. It 
has a trophic effect by enhancing the metabolic function 
of  the mucosa. S. boulardii releases polyamines, which are 
implicated in stimulating the enzymatic activity of  the 
colonic mucosa[3,5].
Based on our previous experience of  use of  S. boulardii 
in the treatment of  diarrhoea, this study was undertaken 
to assess the efficacy of  S. boulardii in the treatment of  
diarrhoea and reoccurrence of  diarrhoea in subsequent 
two months.
MATERIALS AND METHODS
Patients 
This randomised controlled clinical trial was carried out at 
Kharadar General Hospital, Karachi, catering to the needs 
of  approximately one million population and situated in 
the middle and low-income community. An informed 
consent was obtained from parent/guardian of  every child 
included in the trial. The children from 2 mo to 12 years 
of  age presenting with acute watery diarrhoea of  mild 
to moderate severity, fulfilling the inclusion criteria were 
included in this trial.
Children with severe inter-current illnesses, severe diar-
rhoea and dehydration requiring hospitalisation and intra-
venous therapy, presenting with temperature above 38.5℃, 
who were treated by any other anti-diarrhoeal/antibiotics 
in last 24 h as well as severely malnourished children were 
excluded from the trial. At inclusion, stool specimen was 
sent for bacterial culture and sensitivity as well as for Rota 
virus detection.  
The study population of  100 children was randomised 
into two groups. In S. boulardii group, patients were 
managed by WHO-CDD protocol[6] plus S. boulardii (250 
mg bid) administered orally diluted in water or other semi-
solid food. The product was manufactured by Hilton 
Pharma (Pvt) Ltd. under the license of  Biocodex, France. 
In the control group patients were managed by WHO-
CDD protocol only. The active treatment period was 5 d. 
Treatment of  the subsequent episodes of  diarrhoea was at 
the discretion of  the treating physician. 
All study participants were examined on d 0 (inclusion 
day), and followed up on d 3 and d 6 during active 
treatment phase and every month for two months 
thereafter for observation. 
The first visit data collection included date of  onset of  
diarrhoea, previous treatment (where applicable), weight 
of  child, number and consistency of  stools, vomiting, 
body temperature, sign of  dehydration and any other data 
by clinical examination. The second visit information 
variables included date of  stoppage of  diarrhoea in case 
of  inter-current recovery, weight of  child, daily record 
of  frequency and consistency of  stools, tolerance and 
acceptability of  treatment. Similarly on third visit, date of  
stoppage of  diarrhoea in case of  inter-current recovery, 
weight of  child, daily record of  frequency and consistency 
of  stools, tolerance and acceptability of  treatment were 
recorded in the study record forms.
A monthly observational follow-up data for two 
months included weight of  child at monthly interval and 
any new episodes of  diarrhoea in both the groups.
Statistical analysis
For statistical analysis, t-test was applied to measure the 
variation in means. P < 0.05 was taken as significant. 
RESULTS
One hundred patients were analysed in the study, fifty 
patients in each group. Patient baseline characteristics 
in control and study groups were comparable (Table 1). 
Bacteria were isolated in 26% and 12% of  the S. boulardii 
and control groups respectively while Rota virus detection 
Table 1  Baseline characteristics
Patient characteristics S. Boulardii Control
(n  = 50) (n  = 50) P  value
Age (mo)
Mean 18.3   26.01 0.08
SD   20.33   23.37
Weight (kg)
Mean   8.2     9.15   0.224
SD     3.58     4.13
Sex
Female 50% 50%          1
Male 50% 50%
Stool culture/Sensitivity 26%
Bacteria isolated 74% 12%   0.125
Not isolated 88%
Rota virus
Positive 16% 20%   0.795
Negative 84% 80%
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revealed 16% and 20% positive for test and control group 
respectively.  
On d 3 and d 6, there was a significant reduction in re-
ported number of  stools in S. boulardii group as compared 
to the control group. The mean duration of  diarrhoea was 
3.5 d in S. boulardii group and 4.8 d in the control group (P 
= 0.001) (Table 2). 
Follow-up for the next two months also revealed in-
teresting results. Mean numbers of  episodes of  diarrhoea 
by the end of  two months, were 0.56 in control group as 
compared to 0.32 in S. boulardii group, which is almost half  
of  that of  control group (Table 3).
S. boulardii was well accepted and tolerated by the chil-
dren and there were no reports of  any side effects during 
the study period.
Table 4 also shows mean weight gain in both groups at 
mo 1 and 2. Although the difference of  gain between the 
two groups has not reached statistical significance, the per-
centage of  average increase in the experimental group was 
9.9% as compared to 6.2% in the control group. 
DISCUSSION
There are over 109-12 bacteria per gram of  faeces and 
about 400 different species, more than 10 times the 
human cells[7]. The intestinal flora is intimately associated 
with the organ which contains it and with which it forms 
an ecosystem. Equilibrium within this ecosystem is 
essential to good health of  the individual. It influences 
the structure, motility, physical and chemical conditions 
of  intestinal tract, metabolic and enzyme activity of  
mucosa and establishment and maturation of  immune 
system. Finally and above all, the intestinal microbial flora 
forms a true resistance to colonisation of  digestive tract 
by pathogenic microorganisms. Disruption of  intestinal 
ecosystem occurs in many pathological situations such 
as infectious diarrhoea or diarrhoea and colitis linked to 
antibiotic treatment. 
Despite awareness about preventive aspects of  diar-
rhoea it remains one of  the leading causes of  morbidity 
and mortality in children, because of  lack of  clean water 
supply and sanitation.
Search for newer, less harmful agent is continued. Bio-
logical agents ("biotherapeutic agents" or "probiotics") 
have been used to treat a variety of  infections, most nota-
bly infections of  mucosal surfaces such as the gut and va-
gina. These biotherapeutic agents include certain bacteria 
and the yeast S. boulardii. Given orally, S. boulardii seem to 
be promising agents for the amelioration of  the course of  
acute diarrhoea in children[8]. 
The current study was based on our previous clinical 
observation, which revealed that children treated with S. 
boulardii had a decreased number of  episodes of  diarrhoea 
in following months.  
This study verified our previous observation, as there 
was a 50% reduction in the number of  episodes of  di-
arrhoea in the treatment group as compared to control 
group (Table 2). 
This study also showed a significant improvement in 
frequency and consistency of  stool and reduction in dura-
tion of  illness in patients who were given S. boulardii along 
with WHO-CDD protocol.
Several studies of  S. boulardii have been done in chil-
dren and adults in the treatment of  acute diarrhoea[9]. The 
results of  our studies are consistent with some of  these 
studies. However, the current study is the first one to ob-
serve the reduction in number of  episodes of  diarrhoea in 
the post-treatment follow-up period of  two months. Stim-
ulation of  local immunity, as demonstrated by the increase 
of  IgA, together with the enhancement of  the trophic 
activity of  the mucosa (through the release of  polyamines) 
by S. boulardii may, at least in part, explain the long term 
effect of  the yeast.
A meticulous follow-up of  the patient resulted in very 
good compliance. No side effects were observed during 
the active treatment period with the use of  S. boulardii. 
McFarland et al also highlight the safety profile in their 
review on S. boulardi[10].
CONCLUSION 
Based on our experience of  this trial we conclude that S. 
boulardii is a useful and welcome addition to the treatment 
of  acute diarrhoea in children. S. boulardii reduces the 
frequency of  stool, and duration of  illness. It also reduces 
the number of  episodes of  diarrhoea by 50% in the 
subsequent period of  two months.
Though this is the first study of  its kind in Pakistan, we 
are of  the opinion that multicenter double blind placebo 
controlled trials need to be conducted to confirm our 
observations. Investigators have been using probiotics as 
Table 2  Mean numbers of stools and duration of diarrhoea
S. boulardii Control P  value
Mean number of stools reported on d 0 9.5 8.8 0.37
Mean number of stools reported on d 3 2.8 4.4 0.01
Mean number of stools reported on d 6 1.6 3.3   0.001
Duration of diarrhoea (d) 3.6 4.8   0.001
Table 3  Number of episodes of diarrhoea 
S. boulardii Control P  value
No. of episodes at 1 mo 0.2 0.64   0.001
No. of episodes at 2 mo  0.32 0.56 0.04
Table 4  Weight gain 
Group % of mean weight gain P  value
% increase in wt. at 1 mo S. boulardii 4.4
Control 4.2 0.902
% increase in wt. at 2 mo S. boulardii 9.9
Control 6.2 0.067
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prophylaxis in childhood infection whereby it has been 
shown to reduce the rate of  infection[7,11]. 
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